You are on page 1of 2

Benzodiazepines impair psychomotor performance, but neither

ebastine nor mizolastine (both non-sedating antihistamines) further impair this. An
enhanced sedative effect would be expected if
known sedative antihistamines are given with benzodiazepines.
Diphenhydramine did not alter the pharmacokinetics of zaleplon.
Clinical evidence
(a) Diphenhydramine
A randomised single dose three-period crossover study in healthy subjects
found that diphenhydramine 50 mg had no significant effect on the
pharmacokinetics of a single 10-mg dose of zaleplon, despite the fact
diphenhydramine is a moderate inhibitor of the primary metabolic pathway
[aldehyde oxidase] of zaleplon.
(b) Ebastine
Ebastine 20 mg daily did not impair the performance of a number of psychomotor
tests in 12 healthy subjects, although body sway and flicker fusion tests were
altered. When ebastine was given with a single 15-mg dose
of diazepam, it did not further impair performance compared with diazepam alone,
and did not alter plasma diazepamlevels.

(c) Mizolastine
Mizolastine appears to lack sedative effects, and does not have a detrimental effect
on psychomotor performance.

A single 2-mg dose of oral lorazepamwas found to impair the performance of
psychomotor tests in 16
healthy subjects, and caused some sedation and amnesia, but these effects
were not changed when the subjects also took mizolastine 10 mg daily for
8 days.

and this would be expected to be increased by some of the benzodiazepines by the simple addition of their CNS depressant effects. importance and management A number of older antihistamines cause sedation. (p.Mechanism. Non-sedating antihistamines would not be expected to have this effect (but see also ‘Antihistamines’.582)). . and this has been confirmed for ebastine and mizolastine.